Nvidia announces collaboration with Thermo Fisher

At the J.P. Morgan Healthcare Conference, Nvidia (NVDA) announced what it calls “a major expansion” of NVIDIA BioNeMo, an open development platform that enables lab-in-the-loop workflows to develop breakthroughs in AI-driven biology and drug discovery. In conjunction, Nvidia and Eli Lilly and Company (LLY) announced a AI co-innovation lab that they say is “focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry.” In addition, Nvidia says it is collaborating with Thermo Fisher (TMO) to build autonomous lab infrastructure for scalable scientific discovery. “Biology and drug discovery are reaching their transformer moments. BioNeMo turns experimental data into usable intelligence for AI, so every experiment informs the next. This creates a continuous learning cycle that speeds up discovery and helps researchers build new frontier models to tackle some of biology’s toughest challenges,” said Kimberly Powell, vice president of healthcare at Nvidia.